Clinical Trial Update: Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing early switch maintenance with delayed second-line nivolumab in advanced squamous non-small cell lung cancer; results not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Squamous Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN